March 11, 2020 (MLN): GlaxoSmithKline Pakistan Limited has announced the financial results for the year ended December 31, 2019, which show that the company has earned profits of Rs. 3.04 billion (EPS: Rs. 9.55), i.e. around 6% lower than those of previous year.
The company also announced a Cash Dividend for the period at Rs. 6 per share i.e. 60%.
The company’s topline earning surged by 7.5%, while cost of sales increased by 12.8%, causing the gross profit to fall by 8.3%. On the other hand, the non-core income surged by 35% whereas non-core expenses fell by merely 1%.
Financial Results for the year ended March 31, 2019 ('000 Rupees) |
|||
---|---|---|---|
Dec-19 |
Dec-18 |
% Change |
|
Sales |
36,581,749 |
34,006,840 |
7.57% |
Cost of Sales |
(28,870,246) |
(25,593,240) |
12.80% |
Gross Profit |
7,711,503 |
8,413,600 |
-8.34% |
Selling, marketing and distribution expenses |
(3,320,549) |
(3,571,512) |
-7.03% |
Administrative expenses |
(1,098,946) |
(1,076,631) |
2.07% |
Other operating expenses |
(393,563) |
(397,582) |
-1.01% |
Other income |
1,991,462 |
1,471,634 |
35.32% |
Profit from operations |
4,889,907 |
4,839,509 |
1.04% |
Finance cost |
(289,611) |
(147,392) |
96.49% |
Profit before taxation |
4,600,296 |
4,692,117 |
-1.96% |
Taxation |
(1,559,173) |
(1,460,195) |
6.78% |
Profit after taxation |
3,041,123 |
3,231,922 |
-5.90% |
Earnings per share (Rupees) |
9.55 |
10.15 |
-5.91% |
Copyright Mettis Link News
33338